LCMT1 and cancer: This strongly suggests a paradigm where persistent oncogenic PI3K signaling in cancer cells is achieved by the elimination of its negative regulator AB56αC and also other methylation-sensitive heterotrimers such as AB55C through S6K1-mediated degradation of LCMT1.